NO20023035L - Antidiabetispreparat for oral administrering - Google Patents

Antidiabetispreparat for oral administrering

Info

Publication number
NO20023035L
NO20023035L NO20023035A NO20023035A NO20023035L NO 20023035 L NO20023035 L NO 20023035L NO 20023035 A NO20023035 A NO 20023035A NO 20023035 A NO20023035 A NO 20023035A NO 20023035 L NO20023035 L NO 20023035L
Authority
NO
Norway
Prior art keywords
oral administration
antidiabetic preparation
preparation
antidiabetic
prandi
Prior art date
Application number
NO20023035A
Other languages
English (en)
Other versions
NO20023035D0 (no
Inventor
Chisato Makino
Nobutaka Ninomiya
Haruo Orita
Hidetoshi Sakai
Akira Yakubi
Nobuo Kato
Shigeru Shioya
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26582645&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20023035(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of NO20023035D0 publication Critical patent/NO20023035D0/no
Publication of NO20023035L publication Critical patent/NO20023035L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20023035A 1999-12-28 2002-06-21 Antidiabetispreparat for oral administrering NO20023035L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP37495999 1999-12-28
JP2000085159 2000-03-24
PCT/JP2000/009281 WO2001047557A1 (fr) 1999-12-28 2000-12-27 Preparations orales pour diabetes

Publications (2)

Publication Number Publication Date
NO20023035D0 NO20023035D0 (no) 2002-06-21
NO20023035L true NO20023035L (no) 2002-08-21

Family

ID=26582645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023035A NO20023035L (no) 1999-12-28 2002-06-21 Antidiabetispreparat for oral administrering

Country Status (22)

Country Link
US (2) US7022339B2 (no)
EP (2) EP1616561B1 (no)
JP (2) JP4822039B2 (no)
KR (1) KR20020063282A (no)
CN (1) CN1437483A (no)
AT (2) ATE310507T1 (no)
AU (1) AU2226901A (no)
BR (1) BR0016801A (no)
CA (1) CA2395993A1 (no)
CZ (1) CZ20022294A3 (no)
DE (2) DE60039315D1 (no)
ES (2) ES2305977T3 (no)
HK (1) HK1049622A1 (no)
HU (1) HUP0204109A3 (no)
IL (1) IL150294A0 (no)
MX (1) MXPA02006443A (no)
NO (1) NO20023035L (no)
PL (1) PL356300A1 (no)
PT (1) PT1616561E (no)
RU (1) RU2002120498A (no)
SK (1) SK9292002A3 (no)
WO (1) WO2001047557A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204109A3 (en) 1999-12-28 2004-06-28 Ajinomoto Kk Oral preparations for diabetes
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
MXPA03003484A (es) * 2000-10-18 2003-07-14 Ajinomoto Kk Procedimiento para producir cristales de nateglinida.
DE60130575T2 (de) * 2000-10-18 2008-04-30 Ajinomoto Co., Inc. Verfahren zur herstellung von acylphenylalaninen
CN100422143C (zh) * 2000-10-24 2008-10-01 味之素株式会社 那格列奈b型结晶的制造方法
JPWO2002040010A1 (ja) * 2000-10-24 2004-06-03 味の素株式会社 ナテグリニド含有親水性医薬製剤
EP1334720B1 (en) * 2000-10-24 2008-09-03 Ajinomoto Co., Inc. Nateglinide-containing preparations
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
CN1247194C (zh) * 2002-08-27 2006-03-29 石药集团中奇制药技术（石家庄）有限公司 一种那格列奈包合物
EP1537880A4 (en) * 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
CA2504329C (en) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2005016315A1 (en) * 2003-08-14 2005-02-24 Ranbaxy Laboratories Limited Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
BRPI0414512B8 (pt) * 2003-09-17 2021-05-25 Board Of Regentes The Univ Of Texas System composição para reproduzir imagens de um pâncreas e uso desta
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
JP5168712B2 (ja) * 2004-04-01 2013-03-27 味の素株式会社 ナテグリニド含有製剤
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
NZ552841A (en) * 2004-08-04 2009-07-31 Alza Corp Controlled release dosage form comprising two layers, wherein the delay layer is substanially free of non-microencapsulated drug
JP5551852B2 (ja) * 2004-08-10 2014-07-16 味の素株式会社 苦味の低減したナテグリニド含有製剤
CN1660064B (zh) * 2004-12-28 2010-09-29 中山大学 那格列奈自乳化释药系统
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
JP6042330B2 (ja) * 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
WO2013077819A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Pharmaceutical formulations comprising nateglinide
CN107427481A (zh) * 2015-02-09 2017-12-01 安特拉贝欧有限公司 骨质疏松症的治疗
CN107296954A (zh) * 2017-06-09 2017-10-27 王丛飞 一种层粘连蛋白创面保护膜

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124191A (en) * 1872-02-27 Improvement in woven felted fabrics for bonnets
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
IT1226940B (it) * 1988-09-16 1991-02-22 Recordati Chem Pharm Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
JP3949725B2 (ja) * 1996-07-17 2007-07-25 オーソーペディック デザインズ，インコーポレイティド 外科用留め具組立体
DE69740161D1 (de) * 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
JPH10231242A (ja) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
JP3950175B2 (ja) * 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
DK1011673T3 (da) * 1997-06-13 2001-07-09 Novo Nordisk As Hidtil ukendt metode til behandling af nidom
JPH11130696A (ja) * 1997-08-27 1999-05-18 Takeda Chem Ind Ltd 経口徐放性製剤
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP3691685B2 (ja) * 1999-06-22 2005-09-07 株式会社バイオックス 血糖値上昇抑制剤
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
HUP0204109A3 (en) 1999-12-28 2004-06-28 Ajinomoto Kk Oral preparations for diabetes
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
EP1334720B1 (en) 2000-10-24 2008-09-03 Ajinomoto Co., Inc. Nateglinide-containing preparations
JPWO2002040010A1 (ja) 2000-10-24 2004-06-03 味の素株式会社 ナテグリニド含有親水性医薬製剤
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration

Also Published As

Publication number Publication date
IL150294A0 (en) 2002-12-01
EP1616561B1 (en) 2008-06-25
PT1616561E (pt) 2008-07-09
US7022339B2 (en) 2006-04-04
EP1616561A1 (en) 2006-01-18
US20060029669A1 (en) 2006-02-09
BR0016801A (pt) 2002-09-24
NO20023035D0 (no) 2002-06-21
MXPA02006443A (es) 2002-11-29
EP1258249A1 (en) 2002-11-20
DE60024320T2 (de) 2006-08-10
US7488498B2 (en) 2009-02-10
KR20020063282A (ko) 2002-08-01
ATE310507T1 (de) 2005-12-15
DE60024320D1 (de) 2005-12-29
ES2305977T3 (es) 2008-11-01
US20030021843A1 (en) 2003-01-30
AU2226901A (en) 2001-07-09
EP1258249A4 (en) 2003-03-19
HUP0204109A3 (en) 2004-06-28
JP2011153157A (ja) 2011-08-11
HUP0204109A2 (en) 2003-05-28
ES2248159T3 (es) 2006-03-16
ATE399000T1 (de) 2008-07-15
EP1258249B1 (en) 2005-11-23
HK1049622A1 (zh) 2003-05-23
CA2395993A1 (en) 2001-07-05
DE60039315D1 (de) 2008-08-07
SK9292002A3 (en) 2002-10-08
WO2001047557A1 (fr) 2001-07-05
RU2002120498A (ru) 2004-04-10
PL356300A1 (en) 2004-06-28
CZ20022294A3 (cs) 2002-11-13
JP4822039B2 (ja) 2011-11-24
CN1437483A (zh) 2003-08-20

Similar Documents

Publication Publication Date Title
NO20023035D0 (no) Antidiabetispreparat for oral administrering
FI963421A (fi) Oraalisia apuainekoostumuksia
AU1227601A (en) Breakaway devices for stabilizing dental casts
NO20020208L (no) Flytende sammensetninger for oral administrasjon
EE200200273A (et) Uudsed diabeedivastased agensid
ATE303131T1 (de) Zusammensetzungen zur nasalen verabreichung
DK0742715T3 (da) Orale, væskeformige præparater indeholdende paroxetin-resinat
ES2179881T3 (es) Antagonistas de endotelina.
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
EE200400075A (et) Peroraalsed antidiabeetilised ained
NO20034556D0 (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
PT868911E (pt) Formulacoes de rapamicina para administracao oral
DK1231211T3 (da) Thiazolidindion-derivater som antidiabetika
DK0994697T3 (da) Rapamycinformuleringer til oral indgivelse
NO20021452L (no) Orale kontrollerte frigivelsesformuleringer
AU1732401A (en) Medicinal compositions for oral use
NO950403D0 (no) Avvenningssmokk
FI952894A0 (fi) Metyyliundekylenaattiin perustuvat koostumukset hyönteisten torjumiseksi
ITMO990002A0 (it) Articolatore per odontotecnica.
FIU990406U0 (fi) Vieroituslaite
ITBO20010041A0 (it) Dispositivo robotico per impianto orale
DE69901399D1 (de) Piezoelektrischer Schrittantrieb
AUPP915099A0 (en) Improved composition for oral administration
FR2790382B1 (fr) Articulateur dentaire
IT248736Y1 (it) Dispositivo perfezionato per l'ossigeno-ozono terapia.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application